Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) With Oral Decitabine in Patients with Solid Tumors, including Pancreatic Cancer
The purpose of this phase I study is to evaluate the safety and feasibility of decitabine and cedazuridine in patients with solid tumors, including pancreatic cancer.
Study ID: J18115
Trial Phase: Phase I
Trial Sponsor: Johns Hopkins University
Therapies Used in This Trial: Decitabine, Cedazuridine